MX2016000188A - Formas de dosificacion farmaceutica estabilizadas que comprenden atrasentan. - Google Patents

Formas de dosificacion farmaceutica estabilizadas que comprenden atrasentan.

Info

Publication number
MX2016000188A
MX2016000188A MX2016000188A MX2016000188A MX2016000188A MX 2016000188 A MX2016000188 A MX 2016000188A MX 2016000188 A MX2016000188 A MX 2016000188A MX 2016000188 A MX2016000188 A MX 2016000188A MX 2016000188 A MX2016000188 A MX 2016000188A
Authority
MX
Mexico
Prior art keywords
pharmaceutical dosage
dosage forms
atrasentan
methods
stabilized pharmaceutical
Prior art date
Application number
MX2016000188A
Other languages
English (en)
Inventor
Ye Huang
Andrew K Koski
Katherine E Peterson
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2016000188A publication Critical patent/MX2016000188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a: (a) formas de dosificación farmacéutica estabilizadas que comprenden atrasentan, o una sal farmacéuticamente aceptable de los mismos, y, opcionalmente, otro agente terapéutico; (b) métodos para usar tales formas de dosificación farmacéutica para tratar nefropatía, enfermedad renal crónica, y/u otras afecciones; (c) kits que comprenden tales formas de dosificación farmacéutica y, opcionalmente, una segunda forma de dosificación farmacéutica que comprende otro agente terapéutico; (d) métodos para la preparación de tales formas de dosificación farmacéutica; y (e) formas de dosificación farmacéutica preparadas por tales métodos.
MX2016000188A 2013-07-08 2014-07-07 Formas de dosificacion farmaceutica estabilizadas que comprenden atrasentan. MX2016000188A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361843799P 2013-07-08 2013-07-08
PCT/US2014/045581 WO2015006219A1 (en) 2013-07-08 2014-07-07 Stabilized pharmaceutical dosage forms comprising atrasentan

Publications (1)

Publication Number Publication Date
MX2016000188A true MX2016000188A (es) 2016-03-09

Family

ID=51211921

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000188A MX2016000188A (es) 2013-07-08 2014-07-07 Formas de dosificacion farmaceutica estabilizadas que comprenden atrasentan.

Country Status (19)

Country Link
US (2) US9364458B2 (es)
EP (1) EP3019158A1 (es)
JP (1) JP2016530238A (es)
KR (1) KR20160029125A (es)
CN (1) CN105517541A (es)
AU (1) AU2014287496A1 (es)
CA (1) CA2916033C (es)
CL (2) CL2016000027A1 (es)
CR (1) CR20160037A (es)
DO (1) DOP2016000003A (es)
EC (1) ECSP16005195A (es)
HK (1) HK1223825A1 (es)
IL (1) IL243242B (es)
MX (1) MX2016000188A (es)
PE (1) PE20160221A1 (es)
PH (1) PH12016500042A1 (es)
RU (1) RU2016103764A (es)
SG (2) SG11201600107RA (es)
WO (1) WO2015006219A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600107RA (en) * 2013-07-08 2016-02-26 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
US10929741B2 (en) 2018-06-18 2021-02-23 University Of Florida Research Foundation, Incorporated Cross-registration for unclonable chipless RFID tags
TW202130350A (zh) * 2019-12-17 2021-08-16 美商奇努克治療美國公司 用阿曲生坦（ＡＴＲＡＳＥＮＴＡＮ）治療ＩｇＡ腎病的方法
PE20230778A1 (es) 2020-07-10 2023-05-09 Astrazeneca Ab Combinacion de zibotentan y dapagliflozina para el tratamiento de la enfermedad renal cronica
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US6124341A (en) 1996-02-13 2000-09-26 Abbott Laboratories Endothelin antagonists
US5801250A (en) 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2342217C (en) 1998-09-14 2009-12-15 Abbott Laboratories Process for producing stereoselective nitro compounds
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US20030022811A1 (en) 2001-04-11 2003-01-30 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
CA2578824A1 (en) * 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
WO2006034085A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form of atrasentan hydrochloride
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
WO2006034094A1 (en) * 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
CA2644784A1 (en) * 2006-03-13 2007-09-20 Jinling Chen Formulations of sitaxsentan sodium
US20080132710A1 (en) * 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
US20100184026A1 (en) 2009-01-22 2010-07-22 Abbott Laboratories Companion Diagnostic Assays For Endothelin Receptor Antagonists
MX2012007325A (es) * 2009-12-22 2012-07-20 Abbott Lab Capsula de abt-263.
KR20110119108A (ko) 2010-04-26 2011-11-02 울산대학교 산학협력단 포도씨 프로안토시아니딘 추출물을 유효성분으로 함유하는 폐 섬유화증 치료 및 예방용 약학조성물
CN102114005B (zh) * 2010-12-06 2012-12-12 武汉武药科技有限公司 一种波生坦胶囊及其制备方法
SG11201600107RA (en) * 2013-07-08 2016-02-26 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts

Also Published As

Publication number Publication date
PE20160221A1 (es) 2016-05-22
US9364458B2 (en) 2016-06-14
KR20160029125A (ko) 2016-03-14
EP3019158A1 (en) 2016-05-18
JP2016530238A (ja) 2016-09-29
CR20160037A (es) 2016-04-05
CL2016000027A1 (es) 2016-07-22
US20150011602A1 (en) 2015-01-08
DOP2016000003A (es) 2016-02-15
SG11201600107RA (en) 2016-02-26
HK1223825A1 (zh) 2017-08-11
IL243242B (en) 2020-11-30
CA2916033C (en) 2022-08-23
SG10201700596PA (en) 2017-02-27
ECSP16005195A (es) 2017-02-24
WO2015006219A1 (en) 2015-01-15
IL243242A0 (en) 2016-02-29
AU2014287496A1 (en) 2016-01-07
RU2016103764A3 (es) 2018-05-31
US10016393B2 (en) 2018-07-10
CA2916033A1 (en) 2015-01-15
RU2016103764A (ru) 2017-08-11
US20160250186A1 (en) 2016-09-01
CN105517541A (zh) 2016-04-20
CL2016000788A1 (es) 2016-11-11
PH12016500042A1 (en) 2016-03-28

Similar Documents

Publication Publication Date Title
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
CR20150114A (es) Composición farmacéutica recubierta que contiene regorafenib
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
PH12016502353A1 (en) Pharmaceutical composition
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
TW201613577A (en) Pharmaceutical combinations
JO3326B1 (ar) مثبطات إيبوكسي كيتون بروتياز ثلاثي الببتيد
MX2016003065A (es) Sales de mandelato de atrasentan para el tratamiento de enfermedades renales.
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
TN2015000356A1 (en) Bicyclic compounds
EA201490515A1 (ru) Новые ингибиторы rock-киназ
EA201370230A1 (ru) Новые ингибиторы rock
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib